-+ 0.00%
-+ 0.00%
-+ 0.00%

JOHNSON & JOHNSON ANNOUNCES ERLEADA® (APALUTAMIDE) TREATMENT BEFORE AND AFTER SURGERY REDUCES RISK OF RECURRENCE OR DEATH BY 62% VERSUS SURGERY ALONE IN HIGH-RISK PROSTATE CANCER

Reuters·10/24/2026 12:55:09

Please log in to view news